Is hydroxychloroquine beneficial for COVID-19 patients?

被引：61

作者：

Li, Xing ^{[1
]}

Wang, Ying ^{[2
]}

Agostinis, Patrizia ^{[3
]}

Rabson, Arnold ^{[4
]}

Melino, Gerry ^{[5
]}

Carafoli, Ernesto ^{[6
]}

Shi, Yufang ^{[2
,7
]}

Sun, Erwei ^{[1
,8
]}

机构：

[1] Southern Med Univ, Affiliated Hosp 3, Dept Rheumatol & Immunol, 183 Zhongshan Ave West, Guangzhou 510630, Guangdong, Peoples R China

[2] Chinese Acad Sci, Shanghai Inst Nutr & Hlth, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China

[3] Katholieke Univ Leuven, VIB KU Leuven Ctr Canc Biol, Leuven, Belgium

[4] Rutgers State Univ, Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ USA

[5] Univ Roma Tor Vergata, TOR, I-00133 Rome, Italy

[6] Univ Padua, Venetian Inst Mol Med, Rome, Italy

[7] Soochow Univ, State Key Lab Radiat Med & Protect, Affiliated Hosp 1, Inst Translat Med,Med Coll, Suzhou, Peoples R China

[8] Southern Med Univ, Shunde Hosp, Dept Rheumatol & Immunol, Peoples Hosp Shunde 1, Foshan 528000, Guangdong, Peoples R China

来源：

CELL DEATH & DISEASE | 2020年 / 11卷 / 07期

关键词：

ANTIMALARIAL-DRUGS; CHLOROQUINE; INFECTION; INHIBIT; CELLS;

D O I：

10.1038/s41419-020-2721-8

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar cases rapidly emerged around the world(1-3), the World Health Organization (WHO) declared a public health emergency of international concern on January 30, 2020 and pronounced the rapidly spreading coronavirus outbreak as a pandemic on March 11, 2020(4). The virus has reached almost all countries of the globe. As of June 3, 2020, the accumulated confirmed cases reached 6,479,405 with more than 383,013 deaths worldwide. The urgent and emergency care of COVID-19 patients calls for effective drugs, in addition to the beneficial effects of remdesivir(5), to control the disease and halt the pandemic.

引用

页数：6

共 50 条

[41] Hydroxychloroquine-Associated Hypoglycemia in Hemodialysis Patients With COVID-19
Dirim, Ahmet Burak
Demir, Erol
Safak, Seda
Garayeva, Nurana
Ucar, Ali Riza
Oto, Ozgur Akin
Yazici, Halil
Medetalibeyoglu, Alpay
Kose, Murat
Esen, Figen
Yavuz, Serap Simsek
Turkmen, Aydin
KIDNEY INTERNATIONAL REPORTS, 2020, 5 (10): : 1811 - 1814
[42] Hydroxychloroquine and azithromycin as a treatment of COVID-19
Alice Fanin
Jessica Calegari
Anna Beverina
Silvia Tiraboschi
Internal and Emergency Medicine, 2020, 15 : 841 - 843
[43] Chloroquine or hydroxychloroquine for prophylaxis of COVID-19
Principi, Nicola
Esposito, Susanna
LANCET INFECTIOUS DISEASES, 2020, 20 (10): : 1118 - 1118
[44] Hydroxychloroquine with or without Azithromycin in Covid-19
Keane, Michael J.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (02): : 190 - 190
[45] The strange case of hydroxychloroquine and COVID-19
Sciatti, Edoardo
Ceconi, Claudio
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 28 (17) : 1873 - 1874
[46] Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic
Brufsky, Adam
JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (07) : 770 - 775
[47] Hydroxychloroquine as Prophylaxis for COVID-19: A Review
Monti, Manuela
Vertogen, Bernadette
Masini, Carla
Donati, Caterina
Lilli, Claudia
Zingaretti, Chiara
Musuraca, Gerardo
De Giorgi, Ugo
Cerchione, Claudio
Farolfi, Alberto
Cortesi, Pietro
Viale, Pierluigi
Martinelli, Giovanni
Nanni, Oriana
FRONTIERS IN PHARMACOLOGY, 2020, 11
[48] Hydroxychloroquine, TTP, COVID-19, and SLE
Sookaromdee, Pathum
Wiwanitkit, Viroj
TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (01) : 99 - 99
[49] Hydroxychloroquine in the prevention of COVID-19 mortality
Jorge, April
LANCET RHEUMATOLOGY, 2021, 3 (01): : E2 - E3
[50] Hydroxychloroquine and azithromycin as a treatment of COVID-19
Fanin, Alice
Calegari, Jessica
Beverina, Anna
Tiraboschi, Silvia
INTERNAL AND EMERGENCY MEDICINE, 2020, 15 (05) : 841 - 843

← 1 2 3 4 5 →